^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    3d
    Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov)
    P3, N=92, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • cyclophosphamide • nintedanib • fludarabine IV • Actemra IV (tocilizumab) • zolacaptagene autoleucel (BMS-986353)
    3d
    Phase 2 Study of Rapcabtagene Autoleucel in Myositis (clinicaltrials.gov)
    P2, N=123, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2030 --> Feb 2033 | Trial primary completion date: Jul 2029 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • rapcabtagene autoleucel (YTB323)
    3d
    CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease (clinicaltrials.gov)
    P1, N=15, Recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial
    3d
    ALLG NHL44: A Phase 2, Multicenter, Single-Arm Study to Evaluate Polatuzumab vedotin-Rituximab with/without Radiotherapy as a Bridging Therapy in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Prior to CD19 CAR-T Cell Therapy (ACTRN12626000586314)
    P2, N=47, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Polivy (polatuzumab vedotin-piiq)
    5d
    CAR-p40-T: Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Shenzhen University General Hospital
    New P1/2 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    5d
    CAR-T+ASCT: CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. (clinicaltrials.gov)
    P2, N=20, Recruiting, Zhejiang Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation
    |
    cytarabine • Yescarta (axicabtagene ciloleucel) • carmustine • melphalan
    6d
    Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (clinicaltrials.gov)
    P3, N=550, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    6d
    T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel. (PubMed, Int J Hematol)
    Axi-cel demonstrated substantial efficacy in Japanese patients with r/r LBCL. The 2L setting was associated with higher toxicity and numerically higher PFS.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    LDH elevation
    |
    Yescarta (axicabtagene ciloleucel)
    6d
    MB-CART2019.1 in Refractory Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=26, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting | Trial completion date: Dec 2030 --> Aug 2030 | Trial primary completion date: Feb 2030 --> Aug 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    7d
    Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel (clinicaltrials.gov)
    P=N/A, N=32, Not yet recruiting, TG Therapeutics, Inc.
    New trial
    |
    azercabtagene zapreleucel (PBCAR0191)
    9d
    CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=20, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    9d
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Liping Dou
    New P1/2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive